Suven Life Sciences liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
127.70×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
17.69×17.69×3.21×18.99×22.61×
17.69×17.69×3.20×18.94×22.61×
8.38.337.390.983.4
51651652.0243240
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUVEN₹264.20

Suven Life Sciences Limited

· Pharma & Health
₹ CrorePeersVIMTALABSTAKEMcap ₹6,967 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Altman Z-Score (Other Equity as RE)————127.70
Current Ratio22.6118.993.2117.6917.69
Quick Ratio22.6118.943.2017.6917.69
Cash, Equiv & ST Investments83.490.937.38.38.3
Working Capital240.5243.252.0515.8515.8
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.